4Front Ventures Corp.
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001783875
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 17,132,000 USD | 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 10-Q for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −6,403,000 USD | 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | Not reported in XBRL filings since 2015 | ||
| Operating expenses | 9,031,000 USD | 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 1,246,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 326,536,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −48,561,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 913,928,993 shares | At 11 Nov 2024 FY2024 Q3 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 17,132,000 USD | 10-Q filed 14 Nov 2024 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2024 to 30 Jun 2024 FY2024 Q2 | 18,656,000 USD | 10-Q filed 14 Aug 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Mar 2024 FY2024 Q1 | 18,842,000 USD | 10-Q filed 17 May 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Dec 2023 FY2023 | 97,435,000 USD | 10-K filed 15 Apr 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2023 to 30 Sep 2023 FY2024 Q3 | 23,002,000 USD | 10-Q filed 14 Nov 2024 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2023 to 30 Jun 2023 FY2024 Q2 | 27,175,000 USD | 10-Q filed 14 Aug 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Mar 2023 FY2024 Q1 | 26,279,000 USD | 10-Q filed 17 May 2024 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Dec 2022 FY2023 | 107,664,000 USD | 10-K filed 15 Apr 2024 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for 4Front Ventures Corp. on Insider TradesLast 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.